Faculty Research: James Olson

Degrees:
Western Michigan University, Kalamazoo, MI B.S. 1984 Biomedical Sci
Rackham School of Graduate Studies, University of Michigan, Ann Arbor, MI Ph.D. 1989 Pharmacology
University of Michigan Medical School, Ann Arbor, MI M.D. 1991 Medicine

Awards and Professional Activities:
Children’s Oncology Group Young Investigator Award

Burroughs Wellcome Career Award in Biomedical Sciences

Emily Dorfman Fellow, American Brain Tumor Association

American Academy of Pediatrics Resident Research Award

Medical Scientist Training Program Fellow

University of Michigan Regents Fellowship

Duncan McCarthy Award for Pharmacology Research

Michigan Competitive Scholarship

Waldo-Sangren Scholar

Medical Student Research Program Award

Midwest Student Medical Research Forum XVII Award

Western Michigan University Academic Scholarship

Anna C. Norton Memorial Fellowship

Paul V. Sangren Jr. Award

Mortar Board National Honor Society, Chapter President

Phi Eta Sigma and Alpha Lambda Delta National Honor Societies

Areas of Research:

Selected Publications:
Olson JM, Clinical Pharmacology Made Ridiculously Simple. MedMaster, Inc., Miami, 1991; 2nd Ed. 2001.

Selected Articles and Book Chapters:

Greenamyre JT, Olson JM, Penney JB, Young AB. Autoradiographic characterization of N-Methyl-D-Aspartate-, quisqualate-, and kainate-sensitive glutamate binding sites. J. Pharmacol. Exp. Ther. 233: 254-263, 1985.

Olson JM, Greenamyre JT, Penney JB, Young AB. Autoradiographic localization of cerebellar excitatory amino acid binding sites in the mouse. Neurosci. 22: 913-923, 1987.

Olson JM, Ciliax BJ, Mancini WR, Young AB. Presence of peripheral-type benzodiazepine binding sites on human erythrocytes. Eur. J. Pharmacol. 152: 47-53, 1988.

Olson JM, Junck L, Young AB, Penney JB, Mancini WR. Isoquinoline and peripheral-type benzodiazepine binding in gliomas: implications for diagnostic imaging. Cancer Res. 48: 5837-5841, 1988.

Junck L, Olson JM, Ciliax BJ, Koeppe RA, Watkins GL, Jewett JM, McKeever PE, Wieland DM, Kilbourn MR, Mancini WR, Kuhl DE, Greenberg HS, Young AB. Positron emission tomographic imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Annals Neurol. 26: 752-758, 1989.

Junck L, Koeppe RA, Olson JM, Jewett JM, Young AB, Greenberg HS, Kuhl DE. Positron emission tomography imaging of peripheral-type benzodiazepines in brain tumors. In Positron Emission Tomography of Neurotransmitters in Brain, Heart, and Tumors. Kuhl DE, Ed., 1991.

Olson JM, McNeel W, Young AB, Mancini WR. Localization of PK 11195 binding sites to mitochondria of human glioma cells. J. Neuro-Oncology 13:35-42, 1992.

Tapscott SJ, Miller AD, Olson JM, Berger MS, Groudine M, Spence AM. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc. Natl. Acad. Sci. USA 91: 8185-8189, 1994.

Rostomily RC, Bermingham-McDonogh O, Berger MS, Tapscott SJ, Reh TA, Olson JM. Expression of neurogenic bHLH genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997.

Farah MH, Olson JM, Sucic HB, Hume RI, Tapscott SJ, Turner DL. Generation of neurons by transient expression of neural bHLH proteins in mammalian cells. Development 127: 693-702, 2000.

Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, Ross CA, Borchelt DR, Tapscott SJ, Young AB, Cha J-H, Olson JM. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9: 1259-1271, 2000.

Hughes RE, and Olson JM. Therapeutic opportunities in polyglutamine disease. Nature Medicine 7: 419-423, 2001.

Olson JM, Asakura A, Snider L, Hawkes R, Strand A, Stoeck J, Hallahan A, Pritchard J, Tapscott SJ. NeuroD2 is necessary for development and survival of central nervous system neurons. Dev. Biol. 234: 174-187, 2001.

Johnston DL, Olson JM, Benjamin DR. Gastrointestinal stromal tumor in a patient with previous neuroblastoma. J. Ped. Hem. Oncol. 23: 255-256, 2001.

Thomas JG, Olson JM, Tapscott SJ, Zhao LP. An efficient and robust statistical modeling approach to discover differentially expressed genes using genomic expression profiles. Genome Research 11: 1227-1236, 2001.

Kiehl T-R, Olson JM, Pulst S-M. The Hereditary Disease Array Group (HDAG) - Microarrays, models and mechanisms: a collaboration update. Current Genomics 2: 221-229, 2001.

Hughes RE, Lo RS, Davis C, Strand AD, Neal CL, Olson JM, Fields S. Altered transcription in yeast expressing expanded polyglutamine. Proc. Natl. Acad. Sci. USA 98: 13201-13206, 2001.

Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JYH, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442, 2002.

Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, Woods AM, Chan EY, Kooperberg C, Young AB, Tapscott SJ, Olson JM. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 11: 1911-1926, 2002.

Luthi-Carter R, Strand AD, Hanson SA, Kooperberg C, Schilling G, LaSpada AR, Merry DE, Young AB, Ross CA, Borchelt DR, Olson JM. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington’s disease mouse models reveal context-independent effects. Hum. Mol. Genet. 11: 1927-1937, 2002.

Chan EYW, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha J-H J, Aronin N, Hayden MR, Olson JM. Increased huntingtin protein length reduces the severity of polyglutamine-induced gene expression changes in mouse models of Huntington disease. Hum. Mol. Genet. 11: 1939-1951, 2002.

Lieberman AP, Harmison G, Strand AD, Olson JM, Fischbeck KH. Altered androgen receptor function due to polyglutamine expansion. Hum. Mol. Genet. 11: 1967-1976, 2002.

Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, Pritchard J, Kooperberg C, Olson JM, Cattaneo E. Early trans-criptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum. Mol. Genet. 11: 1953-1965, 2002.

Xu XL, Olson JM, Zhao LP. A regression-based method to identify differentially expressed genes in microarray time course studies and its application in an inducible Huntington’s disease transgenic model. Hum. Mol. Genet. 11: 1977-1985, 2002.

Strand AD, Olson JM, Kooperberg C. Estimating the statistical significance of gene expression changes observed with oligonucleotide arrays. Hum. Mol. Genet. 11: 2207-2221, 2002.

Kooperberg C, Sipione S, LeBlanc M, Strand AD, Cattaneo E, Olson JM. Evaluating test statistics to select interesting genes in microarray experiments. Hum. Mol. Genet. 11: 2223-2232, 2002.

Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297: 1559-1561, 2002.

Ditzler S, Stoeck J, LeBlanc M, Kooperberg C, Hansen S, Coppin L, Olson JM. A rapid neurobehavioral assessment reveals that FK506 delays symptom onset in R6/2 Huntington’s disease mice. PreClinica 1(3): 115-126, 2003.

Gilbertson RJ, Hill DA, Hernan R, Kocak M, Geyer R, Olson J, Gajjar A, Rush L, Hamilton RL, Finkelstein SD, Pollack IF. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin. Cancer Res. 9(10 Pt1): 3620-3624, 2003.

Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen R, Geyer JR, Overland RP, Strand AD, Tapscott SJ, Olson JM. BMP- 2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nature Medicine 9(8): 1033-1038, 2003.

Lin CH, Stoeck J, Ravanpay AC, Guillemot F, Tapscott SJ, and Olson JM. Regulation of neuroD2 expression in mouse brain. Dev. Biol. 265: 234-245, 2004.

Olson JM and Hallahan AR. P38 MAP Kinase: a convergence point in cancer therapy. Trends in Molecular Medicine 10(3): 125-129, 2004.

Gulayse I, Hall BJ, Hu S-C, Olson JM, Tapscott SJ, and Ghoshl A. Regulation of thalamocortical patterning by neuroD2. Neuron, in press.